Compare SRI & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | SPRO |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 135.5M |
| IPO Year | 1997 | 2017 |
| Metric | SRI | SPRO |
|---|---|---|
| Price | $5.58 | $2.66 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 300.3K | ★ 332.3K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ 0.15 |
| Revenue | ★ $824,444,000.00 | $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.73 | $300.00 |
| P/E Ratio | ★ N/A | $18.53 |
| Revenue Growth | 18.46 | ★ 39.24 |
| 52 Week Low | $3.59 | $0.58 |
| 52 Week High | $9.71 | $3.09 |
| Indicator | SRI | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 60.90 |
| Support Level | $4.60 | $2.15 |
| Resistance Level | $5.72 | $2.70 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 87.50 | 76.27 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.